Allurion Technologies performs reverse stock split to meet listing requirements
Allurion Technologies performs reverse stock split to meet listing requirements
Updated at: June 18, 2026 at 12:45 AM
Allurion Technologies, a medical device company best known for its innovative, procedure-less swallowable gastric balloon for weight loss, has recently taken significant financial steps to remain listed on major stock exchanges.
Like many small-cap companies facing price volatility, Allurion has used reverse stock splits to consolidate its shares and boost its market price.
In January 2025, the company implemented a 1-for-25 reverse split to address concerns regarding the New York Stock Exchange's minimum bid price requirements.
This move was designed to help the company regain compliance with NYSE listing standards, effectively reducing its outstanding shares from 15 million to approximately 1 million.
While these corporate actions are technical in nature—involving adjustments to equity awards and warrants—they highlight the operational challenges Allurion faces, including revenue contraction and the need to strengthen its overall capital market standing.
